Somatuline sales rose 29.7% at CER to €358 million, beating consensus of €330 million by 8%, or €27 million, driven by limited disruption from generic lanreotide. First-half total sales rose 20.4% as reported, or 23.5% at CER, to €2,190.2 million from €1,819.8 million a year earlier, according to the company's press release. First-half product sales of €2,190 million beat consensus of €2,123 million by 3.2%, or €67 million. The company said an adverse currency effect of around 1% on total sales is expected, based on average June 2026 exchange rates. Guidance assumes accelerated sales growth of the portfolio excluding Somatuline and continued Somatuline growth despite potential entry of generic lanreotide, the company said.